Rowan-Virtua Researchers Developing New Oral Cancer Treatment

Results from an early clinical trial show that a new drug called MASL® holds promise for treating oral squamous cell carcinoma (OSCC). Dr. Gary Goldberg of the Rowan-Virtua School of Osteopathic Medicine and Dr. Mahnaz Fatahzadeh from the Rutgers School of Dental Medicine led the first-in-human phase 1 trial, which was recently published in the Journal of Cancer Research and Clinical Oncology. The results demonstrated the potential of MASL to address critical unmet needs in the treatment of oral cancer, according to the researchers.

Read in News/Medical Life Sciences.